PKO Investment Management Joint Stock Co Has $7.20 Million Stake in Johnson & Johnson $JNJ

Key Points

• PKO Investment Management Joint Stock Co has increased its stake in Johnson & Johnson by 92.5% in Q2, now holding 47,151 shares valued at $7.20 million.
• The company announced a quarterly dividend of $1.30, with an ex-dividend date on November 25th, highlighting a 2.7% dividend yield.
• Johnson & Johnson's recent earnings report revealed an EPS of $2.26 and revenue of $24.02 billion for the quarter, with analysts projecting a consensus target price of $199.05 for the stock.

PKO Investment Management Joint Stock Co increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 92.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,151 shares of the company's stock after buying an additional 22,651 shares during the quarter. PKO Investment Management Joint Stock Co's holdings in Johnson & Johnson were worth $7,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Brighton Jones LLC boosted its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson during the first quarter worth about $218,000. GAMMA Investing LLC grew its holdings in shares of Johnson & Johnson by 48.0% during the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock worth $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Global Assets Advisory LLC boosted its stake in Johnson & Johnson by 187.3% in the first quarter. Global Assets Advisory LLC now owns 19,735 shares of the company's stock worth $2,988,000 after buying an additional 12,866 shares in the last quarter. Finally, Balance Wealth LLC purchased a new stake in Johnson & Johnson in the first quarter worth approximately $274,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $190.38 on Friday. The stock has a market cap of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.07. The stock has a 50 day moving average price of $182.26 and a 200-day moving average price of $166.13. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson's payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a report on Friday, October 3rd. Loop Capital set a $190.00 price target on Johnson & Johnson in a report on Wednesday. Citigroup increased their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, October 15th. Finally, Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $199.05.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.